186 related articles for article (PubMed ID: 33462138)
1. The Phosphoenolpyruvate Carboxykinase Is a Key Metabolic Enzyme and Critical Virulence Factor of
Barazandeh AF; Mou Z; Ikeogu N; Mejia EM; Edechi CA; Zhang WW; Alizadeh J; Hatch GM; Ghavami S; Matlashewski G; Marshall AJ; Uzonna JE
J Immunol; 2021 Mar; 206(5):1013-1026. PubMed ID: 33462138
[TBL] [Abstract][Full Text] [Related]
2. The levels and patterns of cytokines produced by CD4 T lymphocytes of BALB/c mice infected with Leishmania major by inoculation into the ear dermis depend on the infectiousness and size of the inoculum.
Lang T; Courret N; Colle JH; Milon G; Antoine JC
Infect Immun; 2003 May; 71(5):2674-83. PubMed ID: 12704142
[TBL] [Abstract][Full Text] [Related]
3. Leishmania-encoded orthologs of macrophage migration inhibitory factor regulate host immunity to promote parasite persistence.
Holowka T; Castilho TM; Garcia AB; Sun T; McMahon-Pratt D; Bucala R
FASEB J; 2016 Jun; 30(6):2249-65. PubMed ID: 26956417
[TBL] [Abstract][Full Text] [Related]
4. LACK-reactive CD4+ T cells require autocrine IL-2 to mediate susceptibility to Leishmania major.
Gumy A; Aseffa A; Rachinel N; Breton M; Otten L; Tacchini-Cottier F; Röcken M; Doyen N; Acha-Orbea H; Locksley RM; MacDonald HR; Launois P; Louis J
Eur J Immunol; 2006 Jun; 36(6):1465-73. PubMed ID: 16637008
[TBL] [Abstract][Full Text] [Related]
5. Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody.
Colmenares M; Constant SL; Kima PE; McMahon-Pratt D
Infect Immun; 2002 Dec; 70(12):6597-605. PubMed ID: 12438331
[TBL] [Abstract][Full Text] [Related]
6. Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection.
Radwanska M; Cutler AJ; Hoving JC; Magez S; Holscher C; Bohms A; Arendse B; Kirsch R; Hunig T; Alexander J; Kaye P; Brombacher F
PLoS Pathog; 2007 May; 3(5):e68. PubMed ID: 17500591
[TBL] [Abstract][Full Text] [Related]
7. Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.
Elikaee S; Mohebali M; Rezaei S; Eslami H; Khamesipour A; Keshavarz H; Eshraghian MR
Vaccine; 2019 May; 37(24):3221-3228. PubMed ID: 31047672
[TBL] [Abstract][Full Text] [Related]
8. SODB1 is essential for Leishmania major infection of macrophages and pathogenesis in mice.
Davenport BJ; Martin CG; Beverley SM; Orlicky DJ; Vazquez-Torres A; Morrison TE
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006921. PubMed ID: 30372439
[TBL] [Abstract][Full Text] [Related]
9. Leishmania promastigotes evade interleukin 12 (IL-12) induction by macrophages and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection.
Reiner SL; Zheng S; Wang ZE; Stowring L; Locksley RM
J Exp Med; 1994 Feb; 179(2):447-56. PubMed ID: 7905017
[TBL] [Abstract][Full Text] [Related]
10. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
Courret N; Lang T; Milon G; Antoine JC
Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
[TBL] [Abstract][Full Text] [Related]
11. Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major.
Daneshvar H; Burchmore R; Hagan P; Phillips RS
Parasitology; 2009 Sep; 136(11):1243-50. PubMed ID: 19646303
[TBL] [Abstract][Full Text] [Related]
12. BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge.
Ramírez L; Iborra S; Cortés J; Bonay P; Alonso C; Barral-Netto M; Soto M
J Biomed Biotechnol; 2010; 2010():181690. PubMed ID: 20145701
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
Halliday A; Bates PA; Chance ML; Taylor MJ
Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
[TBL] [Abstract][Full Text] [Related]
14. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity.
Belkaid Y; Mendez S; Lira R; Kadambi N; Milon G; Sacks D
J Immunol; 2000 Jul; 165(2):969-77. PubMed ID: 10878373
[TBL] [Abstract][Full Text] [Related]
15. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages.
Prina E; Lang T; Glaichenhaus N; Antoine JC
J Immunol; 1996 Jun; 156(11):4318-27. PubMed ID: 8666803
[TBL] [Abstract][Full Text] [Related]
16. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
[TBL] [Abstract][Full Text] [Related]
17. Acute cysticercosis favours rapid and more severe lesions caused by Leishmania major and Leishmania mexicana infection, a role for alternatively activated macrophages.
Rodríguez-Sosa M; Rivera-Montoya I; Espinoza A; Romero-Grijalva M; López-Flores R; González J; Terrazas LI
Cell Immunol; 2006 Aug; 242(2):61-71. PubMed ID: 17118349
[TBL] [Abstract][Full Text] [Related]
18. Leishmania major parasite stage-dependent host cell invasion and immune evasion.
Wenzel UA; Bank E; Florian C; Förster S; Zimara N; Steinacker J; Klinger M; Reiling N; Ritter U; van Zandbergen G
FASEB J; 2012 Jan; 26(1):29-39. PubMed ID: 21908716
[TBL] [Abstract][Full Text] [Related]
19. Identification of a Protective
Mou Z; Barazandeh AF; Hamana H; Kishi H; Zhang X; Jia P; Ikeogu N; Onyilagha C; Gupta G; Uzonna JE
J Immunol; 2020 Sep; 205(5):1355-1364. PubMed ID: 32727889
[TBL] [Abstract][Full Text] [Related]
20. T cell hypo-responsiveness against Leishmania major in MAP kinase phosphatase (MKP) 2 deficient C57BL/6 mice does not alter the healer disease phenotype.
Schroeder J; McGachy HA; Woods S; Plevin R; Alexander J
PLoS Negl Trop Dis; 2013; 7(2):e2064. PubMed ID: 23437409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
